Related Experiment Video
Updated: Mar 13, 2026
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Proper Technique for Administration of ATX-101 (Deoxycholic Acid Injection): Insights From an Injection Practicum and
Derek H Jones1, Jeffrey M Kenkel, Steven Fagien
1*Department of Dermatology, University of California Los Angeles and Private Practice (Skin Care and Laser Physicians of Beverly Hills), Los Angeles, California; †Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas; ‡Private Practice, Boca Raton, Florida; §Department of Dermatology, Saint Louis University School of Medicine, St. Louis, Missouri; ‖Private Practice (Total Skin & Beauty Dermatology Center, P.C.), Birmingham, Alabama and Departments of Dermatology and Ophthalmology, University of Alabama at Birmingham, Birmingham, Alabama; ¶Evidence Scientific Solutions, Philadelphia, Pennsylvania; **Department of Otolaryngology/Facial Plastic Surgery, University of California Davis Medical Center, Sacramento, California.
ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) is the first aesthetic injectable approved for reduction of submental fat. In February 2014, an injection practicum was conducted in the anatomy laboratory at the University of Texas Southwestern Medical Center to explore the proper injection technique for ATX-101 and the importance of its appropriate, safe anatomical placement within the submental area. Subsequent to the injection practicum, a structured roundtable discussion was conducted in which potential implications of the various injection protocols evaluated during the practicum were reviewed. Furthermore, the faculty had the opportunity to provide additional perspectives based on their clinical experience with facial injectables and ATX-101 specifically. In this article, the findings from the injection practicum and roundtable discussion are reported.
ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) is the first aesthetic injectable approved for reduction of submental fat. In February 2014, an injection practicum was conducted in the anatomy laboratory at the University of Texas Southwestern Medical Center to explore the proper injection technique for ATX-101 and the importance of its appropriate, safe anatomical placement within the submental area. Subsequent to the injection practicum, a structured roundtable discussion was conducted in which potential implications of the various injection protocols evaluated during the practicum were reviewed. Furthermore, the faculty had the opportunity to provide additional perspectives based on their clinical experience with facial injectables and ATX-101 specifically. In this article, the findings from the injection practicum and roundtable discussion are reported.
Related Concept Videos
01:14Prevention of Further Absorption of Poison
01:29Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
01:26Endoscopic Procedures V: ERCP
Patient...
01:25Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...